Reply to S. Cavalieri et al

Sewanti Limaye¹, Prashant Kumar¹, Rajan Datar¹, Aditya Shreenivas¹

Affiliations

Affiliation

¹ Sewanti Limaye, MBBS, MD, MS, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India; Prashant Kumar, PhD, Institute of Bioinformatics, Bangalore, India, Manipal Academy of Higher Education (MAHE), Manipal, India, Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India; Rajan Datar, BE, Datar Cancer Genetics Limited, Nasik, India; and Aditya Shreenivas, MBBS, MD, MS, Department of Medical Oncology, Medical College of Wisconsin, Milwaukee, WI.

PMID: 34994641
DOI: 10.1200/PO.21.00353

Comment

Reply to S. Cavalieri et al

Sewanti Limaye et al. JCO Precis Oncol. 2021 Nov.

. 2021 Nov:5:1528-1529.

doi: 10.1200/PO.21.00353.

Authors

Sewanti Limaye¹, Prashant Kumar¹, Rajan Datar¹, Aditya Shreenivas¹

Affiliation

¹ Sewanti Limaye, MBBS, MD, MS, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India; Prashant Kumar, PhD, Institute of Bioinformatics, Bangalore, India, Manipal Academy of Higher Education (MAHE), Manipal, India, Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India; Rajan Datar, BE, Datar Cancer Genetics Limited, Nasik, India; and Aditya Shreenivas, MBBS, MD, MS, Department of Medical Oncology, Medical College of Wisconsin, Milwaukee, WI.

PMID: 34994641
DOI: 10.1200/PO.21.00353

No abstract available

PubMed Disclaimer

Conflict of interest statement

Prashant KumarEmployment: Datar Cancer GeneticsResearch Funding: Datar Cancer GeneticsPatents, Royalties, Other Intellectual Property: Patent from Singapore for discovery of bladder cancer biomarker Rajan DatarStock and Other Ownership Interest: Datar Cancer GeneticsPatents, Royalties, Other Intellectual Property: Multiple patents related to various technologies developed at Datar Cancer GeneticsNo other potential conflicts of interest were reported.

Comment on

Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
Sheth H, Kumar P, Shreenivas A, Sambath J, Pragya R, Madre C, Athikari N, Khandare H, Peshattiwar V, Datar R, Limaye S. Sheth H, et al. JCO Precis Oncol. 2021 May 3;5:PO.20.00436. doi: 10.1200/PO.20.00436. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34036229 Free PMC article. No abstract available.
An Old but Still Unanswered Question in Recurrent or Metastatic Salivary Duct Carcinoma.
Cavalieri S, Locati LD, Licitra L. Cavalieri S, et al. JCO Precis Oncol. 2021 Nov;5:1526-1527. doi: 10.1200/PO.21.00262. JCO Precis Oncol. 2021. PMID: 34994640 No abstract available.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to S. Cavalieri et al

Affiliation

Reply to S. Cavalieri et al

Authors

Affiliation

Conflict of interest statement

Comment on

Publication types

LinkOut - more resources

Full Text Sources